Current treatment options for gastroenteropancreatic neuroendocrine tumors with a focus on the role of lanreotide.

Kos-Kudla, Beata; Cwikla, Jaroslaw; Ruchala, Marek; Hubalewska-Dydejczyk, Alicja; Jarzab, Barbara; Krajewska, Jolanta; Kaminski, Grzegorz

Kos-Kudla, Beata; Cwikla, Jaroslaw; Ruchala, Marek; Hubalewska-Dydejczyk, Alicja; Jarzab, Barbara; Krajewska, Jolanta; Kaminski, Grzegorz.

Afiliación

Kos-Kudla B; Division of Endocrinology, Department of Pathophysiology and Endocrinology, Silesian Medical University, Katowice, Poland.
Cwikla J; Department of Medical Science, University of Varmia & Masuria, Olsztyn, Poland.
Ruchala M; Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Poznan, Poland.
Hubalewska-Dydejczyk A; Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland.
Jarzab B; Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Krajewska J; Department of Nuclear Medicine and Endocrine Oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland.
Kaminski G; Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.

Contemp Oncol (Pozn) ; 21(2): 115-122, 2017.

Article en En | MEDLINE | ID: mdl-28947880

Palabras clave

CLARINET; GEP-NETs; gastroenteropancreatic neuroendocrine tumors; lanreotide; somatostatin analogue

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Guideline / Screening_studies Idioma: En Revista: Contemp Oncol (Pozn) Año: 2017 Tipo del documento: Article País de afiliación: Polonia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google